Olivier Litzka
Direttore/Membro del Consiglio presso JenaValve Technology GmbH
Patrimonio netto: - $ in data 31/05/2024
Posizioni attive di Olivier Litzka
Società | Posizione | Inizio | Fine |
---|---|---|---|
Andera Partners SCA
Andera Partners SCA Investment ManagersFinance Andera Partners SCA (Andera Partners) is a private equity firm founded in 2001 by Pierre-Michel Passy. The firm is headquartered in Paris, France. | Investitore di Private Equity | 01/10/2006 | - |
JenaValve Technology GmbH
JenaValve Technology GmbH Medical SpecialtiesHealth Technology JenaValve Technology GmbH develops and manufactures transcatheter valve implantation systems for transapical and transfemoral implantation. The firm offers a therapeutic alternative to surgical aortic valve replacement for high-risk patients suffering from aortic heart valve stenosis. The company was founded by Markus Ferrari, Volker Guyenot and Hans-Reiner Figulla in 2006 and is headquartered in Munich, Germany. | Direttore/Membro del Consiglio | - | - |
NOXXON Pharma AG
NOXXON Pharma AG BiotechnologyHealth Technology NOXXON Pharma AG operates a clinical stage biotechnology company. Its core focus is on cancer treatment. The firm offers effectiveness of cancer treatments including immuno-oncology approaches such as immune checkpoint inhibition and current standards of care such as chemotherapy and radiotherapy. The company was founded in 1997 by Sven Klussmann, Jens-Peter Fürste and Thomas Klein and is headquartered in Berlin, Germany. | Direttore/Membro del Consiglio | - | - |
Medlumics SL
Medlumics SL Medical SpecialtiesHealth Technology Medlumics SL provides medical imaging diagnostics services. It specializes in optically guided medical devices. The firm’s proprietary integrated optics platform technology combines optical and electrical components in a miniature chip, enabling for the first time complex multi view optical probes of the size of a grain of rice and ultra-portable, hand-held OCT systems that produces real-time images. The company was founded by Eduardo Margallo Balbás and Jose Luis Rubio Guivernau on April 3, 2009 and is headquartered in Tres Cantos, Spain. | Direttore/Membro del Consiglio | 10/02/2021 | - |
Presidente | - | 10/02/2021 | |
HighLife SAS
HighLife SAS Medical SpecialtiesHealth Technology HighLife SAS develops percutaneous mitral valve replacement therapies. It offers a minimally invasive prosthetic mitral valve that is implanted on a beating heart, while preserving the native valve structure and respecting the surrounding anatomy. The company was founded by Georg Börtle in 2010 and is headquartered in Paris, France. | Direttore/Membro del Consiglio | - | - |
T-Knife GmbH
T-Knife GmbH BiotechnologyHealth Technology T-Knife GmbH operates as an next-generation adoptive T-cell company using its proprietary humanized T-cell receptor mouse platform to treat solid tumors. The company was founded by Thomas Blankenstein, Elisa Kieback and Holger Specht in 2018 and is headquartered in Berlin, Germany. | Direttore/Membro del Consiglio | - | - |
JenaValve Technology, Inc.
JenaValve Technology, Inc. Medical SpecialtiesHealth Technology JenaValve Technology, Inc. designs, develops, manufactures, and markets transcatheter aortic valve replacement systems. The company was founded on March 27, 2006 and is headquartered in Wilmington, DE. | Direttore/Membro del Consiglio | - | - |
Ariceum Therapeutics GmbH
Ariceum Therapeutics GmbH Miscellaneous Commercial ServicesCommercial Services Ariceum Therapeutics GmbH is a German clinical stage radiopharmaceutical company that focuses on the diagnosis and precision treatment of certain neuroendocrine and other aggressive, hard-to-treat cancers. Ariceum Therapeutics is based in Berlin, DE, and has subsidiaries in various locations worldwide. The company's lead targeted systemic radiopharmaceutical product, -satoreotide tetraxetan ("satoreotide"), is an antagonist of the somatostatin type 2 (sstr2) receptor, which is overexpressed in neuroendocrine tumors (NETs) and some aggressive cancers such as small cell lung cancer (SCLC) and Merkel cell carcinoma. Ariceum is also developing a radiolabeled PARP-inhibitor (ATT-001), which is slated to enter the clinic in early 2024. The company was founded in 2021, and Manfred Rüdiger has been the CEO of the company since 2021. | Direttore/Membro del Consiglio | - | - |
Storia della carriera di Olivier Litzka
Precedenti posizioni note di Olivier Litzka
Società | Posizione | Inizio | Fine |
---|---|---|---|
MINERALYS THERAPEUTICS, INC. | Direttore/Membro del Consiglio | 08/05/2022 | 13/06/2024 |
Independent Dir/Board Member | 08/05/2022 | 13/06/2024 | |
░░░ ░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - | ░░░░░░░░░░ |
░░░░░░░░ ░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░░ ░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | - |
░░░░░░░ ░░░░░░░░ ░░░░░ ░░░░░░░░░░░ ░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | - |
░░░░░░░ ░░░░░░░░ ░░░░░ ░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | - |
░░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | - |
░░░░░░░ ░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - | - |
░░░░░░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - | - |
░░░░░░░ ░░░░░░░░░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░ ░░░░░░ ░░░░░░░░░ | ░░░░░░░░░░ | - |
░░░░░░░░ ░░░░░░░ ░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - | - |
░░░░░░░ ░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - | - |
Formazione di Olivier Litzka
Institut Für Medizinische Mikrobiologie | Doctorate Degree |
Statistiche
Distribuzione geografica
Germania | 9 |
Francia | 6 |
Svizzera | 4 |
Posizioni
Director/Board Member | 18 |
Private Equity Investor | 1 |
Doctorate Degree | 1 |
Settori
Health Technology | 16 |
Electronic Technology | 3 |
Finance | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 3 |
---|---|
VIVORYON THERAPEUTICS N.V. | Health Technology |
TME PHARMA N.V. | Health Technology |
MINERALYS THERAPEUTICS, INC. | Health Technology |
Aziende private | 17 |
---|---|
Novexel SA
Novexel SA Pharmaceuticals: MajorHealth Technology Novexel SA researches and develops anti-infective drugs for the treatment of bacterial and fungal infections. The firm focuses on discovery and development of novel antibiotics designed to overcome the significant global problem of microbial resistance. The company was founded in December 2004 and is headquartered in Romainville, France. | Health Technology |
Andera Partners SCA
Andera Partners SCA Investment ManagersFinance Andera Partners SCA (Andera Partners) is a private equity firm founded in 2001 by Pierre-Michel Passy. The firm is headquartered in Paris, France. | Finance |
JenaValve Technology GmbH
JenaValve Technology GmbH Medical SpecialtiesHealth Technology JenaValve Technology GmbH develops and manufactures transcatheter valve implantation systems for transapical and transfemoral implantation. The firm offers a therapeutic alternative to surgical aortic valve replacement for high-risk patients suffering from aortic heart valve stenosis. The company was founded by Markus Ferrari, Volker Guyenot and Hans-Reiner Figulla in 2006 and is headquartered in Munich, Germany. | Health Technology |
ENDOSENSE SA
ENDOSENSE SA Medical SpecialtiesHealth Technology Endosense SA operated as a medical technology company, which focused on reproducibility of catheter ablation for the treatment of cardiac arrhythmias. The firm's flagship product was TactiCath Quartz that helped physicians to measure contact force during the catheter ablation procedure. The company was founded by Vitali Verin, Giovanni Leo, and Nicolas Aeby in 2003 and was headquartered in Geneva, Switzerland. | Health Technology |
Sapiens Steering Brain Stimulation BV
Sapiens Steering Brain Stimulation BV Electronic Equipment/InstrumentsElectronic Technology Sapiens Steering Brain Stimulation BV develops medical devices. The company was founded by Sjaak Deckers in 2011 and is headquartered in Eindhoven, the Netherlands. | Electronic Technology |
Sapiens Steering Brain Stimulation GmbH
Sapiens Steering Brain Stimulation GmbH Medical SpecialtiesHealth Technology Sapiens Steering Brain Stimulation GmbH develops and markets steering deep brain stimulation (DBS) solutions. The firm specializes in the research, design, and delivery of medical solutions to patients suffering from degenerative or functional brain disorders, such as Parkinson’s disease and dystonia. Its product offerings encompass micro-fabricated probes, neurostimulators, and the SureSuite technology, which act as a unified surgical procedure platform. Its SurePlan, SurePlace, and SureTune products provide an integrated and image-based solution for planning and programming an optimal DBS treatment. The company was founded by Sjaak Deckers, Michel Decré and Hubert Martens in 2011 and is headquartered in Munich, Germany. | Health Technology |
SuperSonic Imagine SA
SuperSonic Imagine SA Medical SpecialtiesHealth Technology SuperSonic Imagine SA specializes in ultrasound medical imaging. The company designs, develops and markets a new generation ultrasound system, Aixplorer with an UltraFastTM platform that can acquire images faster than conventional ultrasound systems. Its products are used for general imaging, vascular, hepatology, gastroenterology, and research procedures. It operates under the Aixplorer trademark. SuperSonic Imagine was founded by Jacques Souquet, Armen Sarvazyan, Claude Cohen-Bacrie, Damien Dolimier, Georges Charpak, Jérémy Bercoff, Mickaël Tanter, Mathias Fink and Marianne Leven on March 10, 2005 and is headquartered in Aix-en-Provence, France. | Health Technology |
Allecra Therapeutics GmbH
Allecra Therapeutics GmbH Pharmaceuticals: MajorHealth Technology Allecra Therapeutics GmbH focuses on the development of novel treatments to combat multi drug-resistant bacterial infections. The firm serves the bio and pharmaceutical industry. The company was founded by Nicholas Benedict and Stuart Shapiro in 2013 and is headquartered in Weil am Rhein, Germany. | Health Technology |
NOXXON Pharma AG
NOXXON Pharma AG BiotechnologyHealth Technology NOXXON Pharma AG operates a clinical stage biotechnology company. Its core focus is on cancer treatment. The firm offers effectiveness of cancer treatments including immuno-oncology approaches such as immune checkpoint inhibition and current standards of care such as chemotherapy and radiotherapy. The company was founded in 1997 by Sven Klussmann, Jens-Peter Fürste and Thomas Klein and is headquartered in Berlin, Germany. | Health Technology |
Parvulus Medical SAS | Distribution Services |
Autonomic Technologies, Inc.
Autonomic Technologies, Inc. Electronic Equipment/InstrumentsElectronic Technology Autonomic Technologies, Inc. develops and commercializes innovative therapies for the treatment of severe headache. Its product, the ATI Neurostimulation System, is used for the treatment of acute pain of cluster headache. The company was founded in 2007 and is headquartered in Redwood City, CA. | Electronic Technology |
Medlumics SL
Medlumics SL Medical SpecialtiesHealth Technology Medlumics SL provides medical imaging diagnostics services. It specializes in optically guided medical devices. The firm’s proprietary integrated optics platform technology combines optical and electrical components in a miniature chip, enabling for the first time complex multi view optical probes of the size of a grain of rice and ultra-portable, hand-held OCT systems that produces real-time images. The company was founded by Eduardo Margallo Balbás and Jose Luis Rubio Guivernau on April 3, 2009 and is headquartered in Tres Cantos, Spain. | Health Technology |
HighLife SAS
HighLife SAS Medical SpecialtiesHealth Technology HighLife SAS develops percutaneous mitral valve replacement therapies. It offers a minimally invasive prosthetic mitral valve that is implanted on a beating heart, while preserving the native valve structure and respecting the surrounding anatomy. The company was founded by Georg Börtle in 2010 and is headquartered in Paris, France. | Health Technology |
T-Knife GmbH
T-Knife GmbH BiotechnologyHealth Technology T-Knife GmbH operates as an next-generation adoptive T-cell company using its proprietary humanized T-cell receptor mouse platform to treat solid tumors. The company was founded by Thomas Blankenstein, Elisa Kieback and Holger Specht in 2018 and is headquartered in Berlin, Germany. | Health Technology |
Arvelle Therapeutics International GmbH
Arvelle Therapeutics International GmbH BiotechnologyHealth Technology Arvelle Therapeutics GmbH provides treatment for patients suffering form CNS disorders. The company was founded by Ilise Lombrado, Gregory Mark Weinhoff and Mark Altmeyer and is headquartered in Basel, Switzerland. | Health Technology |
JenaValve Technology, Inc.
JenaValve Technology, Inc. Medical SpecialtiesHealth Technology JenaValve Technology, Inc. designs, develops, manufactures, and markets transcatheter aortic valve replacement systems. The company was founded on March 27, 2006 and is headquartered in Wilmington, DE. | Health Technology |
Ariceum Therapeutics GmbH
Ariceum Therapeutics GmbH Miscellaneous Commercial ServicesCommercial Services Ariceum Therapeutics GmbH is a German clinical stage radiopharmaceutical company that focuses on the diagnosis and precision treatment of certain neuroendocrine and other aggressive, hard-to-treat cancers. Ariceum Therapeutics is based in Berlin, DE, and has subsidiaries in various locations worldwide. The company's lead targeted systemic radiopharmaceutical product, -satoreotide tetraxetan ("satoreotide"), is an antagonist of the somatostatin type 2 (sstr2) receptor, which is overexpressed in neuroendocrine tumors (NETs) and some aggressive cancers such as small cell lung cancer (SCLC) and Merkel cell carcinoma. Ariceum is also developing a radiolabeled PARP-inhibitor (ATT-001), which is slated to enter the clinic in early 2024. The company was founded in 2021, and Manfred Rüdiger has been the CEO of the company since 2021. | Commercial Services |
- Borsa valori
- Insiders
- Olivier Litzka
- Esperienza